Interpectoral-pectoserratus Plane Block for Minimally Invasive Aortic Valve Replacement Via Right Anterior Minithoracotomy: a Single Centre, Prospective, Double-blind, Randomized Controlled Superiority Trial
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 144
- 试验地点
- 1
- 主要终点
- Cumulative opioid consumption
研究概览
简要总结
The goal of this clinical trial is to evaluate the analgesic effect of locoregional anaesthesia, specifically the interpectoral pectoserratus plane (IPP-PSP) block, in comparison to a placebo (sham block) after Aortic Valve Replacement via Right Anterior Minithoracotomy (AVR-RAT). The main question the trial aims to answer is: Can the IPP-PSP block effectively reduce opioid consumption within the first 48 hours after AVR-RAT surgery? The purpose is to understand the impact of the IPP-PSP block on postoperative pain. Therefore, the aim is to investigate the influence of the IPP-PSP block on the amount of pain medication administered during the patients' first 48 hours after surgery.
Participants, who are scheduled for AVR-RAT surgery, will be randomly assigned to receive either the IPP-PSP block or the sham block. Researchers will compare opioid consumption among other outcomes, including differences in pain scores, incidence of nausea and vomiting, quality of recovery, quality of life, and the length of hospital stay between the two groups.
Patients will be monitored during their hospitalization, and a follow-up phone call will be conducted 30 days after surgery.
详细描述
This clinical trial aims to evaluate the analgesic effect of an interpectoral-pectoserratus plane (IPP-PSP) block compared to a placebo (sham block) in patients undergoing aortic valve replacement via right anterior minithoracotomy (AVR-RAT). The primary objective is to determine whether the IPP-PSP block effectively reduces opioid consumption during the first 28 hours post-surgery.
The trial is designed as a single-center, prospective, double-blind, randomized controlled superiority trial. It will enroll adult patients aged 18 years or older who are scheduled for minimally invasive AVR-RAT and meet specific inclusion criteria. Exclusion criteria are established to ensure the safety and integrity of the trial.
Patients undergoing minimally invasive AVR-RAT will be randomly assigned to either the IPP-PSP block group or the sham block group.
The primary endpoint of the trial is the cumulative opioid consumption (in oral morphine milligram equivalents (OMEs)) within the first 48 postoperative hours after completion of the surgical procedure. Secondary outcomes include the number of episodes of postoperative pain, time to need for rescue medication, incidence of respiratory complications, PaCO2 levels, postsurgical recovery, episodes of postoperative nausea and vomiting, time to extubation in the Intensive Care Unit (ICU), ICU length of stay, hospital length of stay, quality of life, number of days alive and at home after surgery, and vital status at 30 days post-operative.
The trial aims to enroll a total of 144 patients, with 72 patients randomized into each group. Blinding will be implemented, meaning neither the participant, anesthesiologist, study nurse, surgeon, nor the doctors and nurses in the Intensive Care Unit will know the participant's group assignment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
盲法说明
Neither the participant, anesthesiologist, study nurse, surgeon, nor the doctors and nurses in the Intensive Care Unit will know the participant's group assignment.
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult patients (18 years of age or older);
- •Patients scheduled for minimally invasive aortic valve replacement via right anterior minithoracotomy;
- •Patients with American Society of Anesthesiologists (ASA) physical status classification II, III or IV;
- •Patients with European System for Cardiac Operative Risk Evaluation (EuroSCORE) 2 ≤ 4%;
- •Patient has given written, free and informed consent.
排除标准
- •BMI > 35;
- •Patients under legal protection (curatorship, guardianship);
- •Patients subject to a legal protection measure;
- •An adult who is incapable or unable to give consent;
- •Patients requiring emergency surgery within 24 hours;
- •Chronic opioid use (> 3 administrations per week or continuous transdermal therapy, longer than the last 3 months);
- •Patients known with chronic pain;
- •Patients known with an allergy to levobupivacaine or drugs used as standard of care, including amongst others piritramide, dexamethasone, propofol, remifentanil, rocuronium, acetaminophen, ondansetron;
- •Patients who receive medication that could possibly interact with levobupivacaine (mexiletine, ketoconazole, theophylline);
- •Patients who took monoamine oxidase (MAO) inhibitors within the last 2 weeks before surgery;
- •Patients with chronic renal failure (dialysis dependent, estimated glomerular filtration rate (eGFR) < 30 ml.min-1.(1,73 m²)-1) ;
- •Patients with severe hepatic impairment (Model for End-Stage Liver Disease (MELD) score ≥ 20);
- •Patients with preoperative cognitive dysfunction (Mini Mental State Examination (MMSE) score < 24);
- •Patients with uncontrolled epilepsy;
- •Patients with severe arterial hypotension (Systolic Arterial Pressure (SAP) < 90 mmHg, cardiogenic shock);
- •Patients who simultaneously participate in another interventional clinical trial;
- •Soft tissue infection in the area of the procedure;
- •Patients who are pregnant, parturient or breast-feeding women;
- •Patients who are unable to sufficiently speak and write in the Dutch language.
研究组 & 干预措施
Levobupivacaine Hydrochloride 0.25 % Injectable Solution
Unilateral (right) IPP-PSP block with 30 mL levobupivacaine 0.25%, administered after the closure of the wounds. After wound closure, the IPP-PSP block is performed at the level of the 4th rib. At the pre-axillary line, the pectoralis major, the pectoralis minor and the serratus anterior muscle are identified. At first, the needle is positioned in the fascial plane between the pectoralis minor and the serratus anterior muscle. The needle position is confirmed by hydro-dissection of this plane with 2 mL of normal saline 0.9%.The 20 ml syringe with trial drug solution is injected in this pectoserratus plane (PSP). The needle tip is repositioned in the interpectoral plane between both the pectoralis major and minor muscle. The 10 ml syringe with trial drug solution is administered in this interpectoral plane (IPP).
干预措施: Levobupivacaine Hydrochloride 0.25 % Injectable Solution (Drug)
Sodium chloride 0.9%
Unilateral (right) IPP-PSP block with 30 mL normal saline 0.9%, administered after the closure of the wounds. Unilateral (right) IPP-PSP block with 30 mL normal saline 0.9%, administered after the closure of the wounds. The IPP-PSP block procedure will be carried out as described in the Active Comparator.
干预措施: Sodium chloride 0.9% (Drug)
结局指标
主要结局
Cumulative opioid consumption
时间窗: in the first 48 hours after completion of the surgical procedure
Cumulative opioid consumption (in oral morphine milligram equivalents (OMEs)) in the first 48 postoperative hours after the completion of the surgical procedure
次要结局
- Number of episodes of postoperative pain(In the first 48 hours after completion of the surgical procedure)
- Time to need for rescue medication(In the first 48 hours after completion of the surgical procedure)
- Number of patients with respiratory complications(During hospital stay (on average 7 days))
- PaCO2 levels(During the 48 postoperative hours after the completion of the surgical procedure or until Intensive Care Unit (ICU) discharge, whichever occurs first;)
- Postsurgical Quality of Recovery measured by the Quality of Recovery questionnaire(Day before, first, second and seventh day after surgery)
- Number of episodes of postoperative nausea and vomiting(Number of episodes of postoperative nausea and vomiting (PONV) in the first 48 postoperative hours after the completion of the surgical procedure: nausea yes/no, vomiting: yes/no)
- Time to extubation(Minutes (assessed up to 6 hours after surgery))
- Number of hours spent in the Intensive Care Unit(Hours (on average 48 hours))
- Hospitalization duration(Days (on average 7 days))
- Days alive and at home(30 (+7) days after surgery)
- Vital status (whether the patient is alive or dead)(30 (+7) days after surgery)
- Quality of life measured by the 5 level version of the EuroQoL-5 Dimension questionnaire(Day before and 30 days after surgery)
研究者
Bart Vaes, MD
Principal Investigator
Algemeen Ziekenhuis Maria Middelares